Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?

A phase I trial of LBH589 and bevacizumab for recurrent high-grade glioma (HGG).

(2017) J. Drappatz et al.   JOURNAL OF CLINICAL ONCOLOGY

Preliminary results from a multicenter, phase II, randomized, noncomparative clinical trial of radiation and temozolomide with or without vandetanib in newly diagnosed glioblastoma (GBM).

(2017) E. C. Quant et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma

(2017) Sith Sathornsumetee et al.   NEURO-ONCOLOGY

Sequential Immunotherapy by Vaccination With GM-CSF–expressing Glioma Cells and CTLA-4 Blockade Effectively Treats Established Murine Intracranial Tumors

(2012) Pankaj Agarwalla et al.   JOURNAL OF IMMUNOTHERAPY

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

(2012) Annika Malmström et al.   LANCET ONCOLOGY

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

(2012) Wolfgang Wick et al.   LANCET ONCOLOGY

Phase 2 trial design in neuro-oncology revisited: a report from the RANO group

(2012) Evanthia Galanis et al.   LANCET ONCOLOGY

Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma

(2012) Jeremy Schwartzentruber et al.   NATURE

Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas

(2012) Gang Wu et al.   NATURE GENETICS

Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma

(2012) B. M. Ellingson et al.   NEURO-ONCOLOGY

Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria

(2012) J. G. Perez-Larraya et al.   NEURO-ONCOLOGY

Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival

(2012) L. S. Hu et al.   NEURO-ONCOLOGY

Cancer Immunoediting in Malignant Glioma

(2012) Gavin P. Dunn et al.   NEUROSURGERY

Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma

(2012) Aleksandar Sekulic et al.   NEW ENGLAND JOURNAL OF MEDICINE

Monitoring of Regulatory T Cell Frequencies and Expression of CTLA-4 on T Cells, before and after DC Vaccination, Can Predict Survival in GBM Patients

(2012) Brendan Fong et al.   PLoS One

Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response

(2012) N. J. Szerlip et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Detection of 2-Hydroxyglutarate in IDH-Mutated Glioma Patients by In Vivo Spectral-Editing and 2D Correlation Magnetic Resonance Spectroscopy

(2012) O. C. Andronesi et al.   Science Translational Medicine

Pharmaco-economic aspects of Sipuleucel-T

(2012) Steven Simoens   Human Vaccines & Immunotherapeutics

Mosaic Amplification of Multiple Receptor Tyrosine Kinase Genes in Glioblastoma

(2011) Matija Snuderl et al.   CANCER CELL

A Hypermethylated Phenotype Is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951

(2011) M. J. van den Bent et al.   CLINICAL CANCER RESEARCH

Vaccines for glioblastoma and high-grade glioma

(2011) Christopher J Wheeler et al.   Expert Review of Vaccines

It Is Time to Include Patients With Brain Tumors in Phase I Trials in Oncology

(2011) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study

(2011) John F. de Groot et al.   JOURNAL OF CLINICAL ONCOLOGY

Rapid Radiographic and Clinical Improvement After Treatment of a MET-Amplified Recurrent Glioblastoma With a Mesenchymal-Epithelial Transition Inhibitor

(2011) Andrew S. Chi et al.   JOURNAL OF CLINICAL ONCOLOGY

A Sensitive and Specific Diagnostic Panel to Distinguish Diffuse Astrocytoma From Astrocytosis: Chromosome 7 Gain With Mutant Isocitrate Dehydrogenase 1 and p53

(2011) Sandra Camelo-Piragua et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma

(2011) A. L. Rivera et al.   NEURO-ONCOLOGY

A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas

(2011) Teri N. Kreisl et al.   NEURO-ONCOLOGY

Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study

(2011) B. B. Friday et al.   NEURO-ONCOLOGY

Clinical trial end points for high-grade glioma: the evolving landscape

(2011) D. A. Reardon et al.   NEURO-ONCOLOGY

Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma

(2011) M. Weller et al.   NEUROLOGY

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Recurrent Glioblastoma: A Fresh Look at Current Therapies and Emerging Novel Approaches

(2011) Mark R. Gilbert   SEMINARS IN ONCOLOGY

Diffusion and Diffusion Tensor Imaging in Brain Cancer

(2011) Elizabeth R. Gerstner et al.   SEMINARS IN RADIATION ONCOLOGY

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas

(2010) Christian Hartmann et al.   ACTA NEUROPATHOLOGICA

Bevacizumab does not increase the risk of remote relapse in malignant glioma

(2010) Antje Wick et al.   ANNALS OF NEUROLOGY

Gone FISHing: Clinical Lessons Learned in Brain Tumor Molecular Diagnostics over the Last Decade

(2010) Craig Horbinski et al.   BRAIN PATHOLOGY

Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme

(2010) John D. Hainsworth et al.   CANCER

Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma

(2010) Houtan Noushmehr et al.   CANCER CELL

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL

Pharmacologic Inhibition of Cyclin-Dependent Kinases 4 and 6 Arrests the Growth of Glioblastoma Multiforme Intracranial Xenografts

(2010) K. Michaud et al.   CANCER RESEARCH

Survival of Patients with Newly Diagnosed Glioblastoma Treated with Radiation and Temozolomide in Research Studies in the United States

(2010) S. A. Grossman et al.   CLINICAL CANCER RESEARCH

Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine

(2010) Dora Dias-Santagata et al.   EMBO Molecular Medicine

Glioma stem cell signaling: therapeutic opportunities and challenges

(2010) Jörg Dietrich et al.   Expert Review of Anticancer Therapy

American Society of Clinical Oncology 2010: report of selected studies from the CNS tumors section

(2010) Patrick Y Wen   Expert Review of Anticancer Therapy

Phase I Study of Vandetanib With Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma

(2010) Jan Drappatz et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma

(2010) Roger Stupp et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

(2010) John H. Sampson et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma

(2010) Tracy T. Batchelor et al.   JOURNAL OF CLINICAL ONCOLOGY

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme

(2010) Albert Lai et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma

(2010) David A. Reardon et al.   JOURNAL OF NEURO-ONCOLOGY

Radiographic patterns of relapse in glioblastoma

(2010) Marc C. Chamberlain   JOURNAL OF NEURO-ONCOLOGY

Phase II study of sunitinib malate in patients with recurrent high-grade glioma

(2010) B. Neyns et al.   JOURNAL OF NEURO-ONCOLOGY

Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma

(2010) Surasak Phuphanich et al.   JOURNAL OF NEURO-ONCOLOGY

Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers

(2010) Michael Jansen et al.   LANCET NEUROLOGY

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Crosstalk Between the PI3K/mTOR and MEK/ERK Pathways Involved in the Maintenance of Self-Renewal and Tumorigenicity of Glioblastoma Stem-Like Cells

(2010) Jun Sunayama et al.   STEM CELLS

Inhibition of Notch Signaling in Glioblastoma Targets Cancer Stem Cells via an Endothelial Cell Intermediate

(2010) Koos E. Hovinga et al.   STEM CELLS

Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma

(2009) B. Neyns et al.   ANNALS OF ONCOLOGY

Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma

(2009) D A Reardon et al.   BRITISH JOURNAL OF CANCER

A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation

(2009) Brian Thiessen et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients

(2009) A. Gregory Sorensen et al.   CANCER RESEARCH

Genetic alterations and signaling pathways in the evolution of gliomas

(2009) Hiroko Ohgaki et al.   CANCER SCIENCE

The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research

(2009) M. A. Cheever et al.   CLINICAL CANCER RESEARCH

DCVax®-Brain and DC vaccines in the treatment of GBM

(2009) Christopher J Wheeler et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

MGMTPromoter Methylation Is Prognostic but Not Predictive for Outcome to Adjuvant PCV Chemotherapy in Anaplastic Oligodendroglial Tumors: A Report From EORTC Brain Tumor Group Study 26951

(2009) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study

(2009) Evanthia Galanis et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

(2009) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide

(2009) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide

(2009) Gregor Dresemann et al.   JOURNAL OF NEURO-ONCOLOGY

Neurological adverse effects caused by cytotoxic and targeted therapies

(2009) David Schiff et al.   Nature Reviews Clinical Oncology

Antiangiogenic therapies for high-grade glioma

(2009) Andrew D. Norden et al.   Nature Reviews Neurology

Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab

(2009) Eudocia C. Quant et al.   NEURO-ONCOLOGY

MGMT METHYLATION IS A PROGNOSTIC BIOMARKER IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA

(2009) E. R. Gerstner et al.   NEUROLOGY

Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma

(2009) F. M. Iwamoto et al.   NEUROLOGY

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

FDA Drug Approval Summary: Bevacizumab (Avastin(R)) as Treatment of Recurrent Glioblastoma Multiforme

(2009) M. H. Cohen et al.   ONCOLOGIST

Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity

(2008) Monika E. Hegi et al.   JOURNAL OF CLINICAL ONCOLOGY

MGMTPromoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients

(2008) Alba A. Brandes et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme

(2008) David A. Reardon et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177

(2008) Paul D. Brown et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY

A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM)

(2008) Teri N. Kreisl et al.   JOURNAL OF NEURO-ONCOLOGY

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

(2008) Roger McLendon et al.   NATURE

Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers

(2008) Johan Skog et al.   NATURE CELL BIOLOGY

Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence

(2008) A. D. Norden et al.   NEUROLOGY

Tumor Angiogenesis

(2008) Robert S. Kerbel   NEW ENGLAND JOURNAL OF MEDICINE

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE

Response criteria for glioma

(2008) A Gregory Sorensen et al.   Nature clinical practice. Oncology

Mechanisms of Disease: the role of stem cells in the biology and treatment of gliomas

(2008) Jörg Dietrich et al.   Nature clinical practice. Oncology